Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The 'Virus' Technology That Kills Coronavirus Plus Lots of Other Pathogens

TOMI Environmental Solutions Inc.'s (TOMZ:OTCQB) products kill pathogens—safely and effectively. Not just the coronavirus: Ebola, MERS, C. diff spores, sepsis, norovirus, anthrax, Staphylococcus, MRSA, Legionnaire's and Zika. The kill list also includes food borne illnes...
Streetwise Reports | February 19, 2020 |

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. On Wednesday morning, T2 BioSystems Inc. (TTOO:NASDAQ) announced receipt of funding from the U.S. Department of Health a...
Streetwise Reports | September 12, 2019 |

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |

Vir Biotech Shares Rise on Joint Research Efforts with the NIH to Combat Coronaviruses

Vir Biotechnology shares traded higher after the company reported that it has entered into a research collaboration with the National Institutes of Health Vaccine Research Center on antibodies against coronaviruses including SARS-CoV-2. Clinical-stage immuno...
Streetwise Reports | March 12, 2020 |

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. Diagnostic...
Streetwise Reports | March 26, 2020 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |

Pandemic fears: real and imagined

“Pandemic”. Few words in the English language conjure as much fear. The mere utterance evokes images of dying patients, surgical masks, haz-mat suits, a parade of coffins, helpless doctors and nurses, as the contagion spreads, first striking down the el...
Richard (Rick) Mills | February 25, 2020 |

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Co

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary Source: Gail Dutton of The Life Sciences Report (12/22/15) https://www.thelifesciencesreport.com/pub/na/aethlon-medical...
Gail Dutton | December 23, 2015 |

Bacteria Test Developer Reiterates Revenue Should Double in 2019

The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. In a May 31 research note, analyst Ram Selvaraju reported that H.C. Wainwright & Co. lowered its target price on T2 BioSystems Inc. (TTOO:NASDAQ) to $10 per sha...
Streetwise Reports | June 10, 2019 |

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

Shares of Paratek Pharmaceuticals traded 40% higher today after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. Late yesterday afternoon, biopharmaceutical company Paratek Pharmaceuti...
Streetwise Reports | December 20, 2019 |
1 2 3